Cargando…
Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial
INTRODUCTION: Strong centrally acting analgesics, including tapentadol prolonged release (PR), have demonstrated efficacy for the management of non-malignant, chronic pain. Maintaining patient independence, including the ability to drive safely, is a key goal of long-term analgesic therapy. This mul...
Autores principales: | Sabatowski, Rainer, Scharnagel, Rüdiger, Gyllensvärd, Anne, Steigerwald, Ilona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108021/ https://www.ncbi.nlm.nih.gov/pubmed/25135385 http://dx.doi.org/10.1007/s40122-014-0025-3 |
Ejemplares similares
-
Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study
por: Steigerwald, Ilona, et al.
Publicado: (2012) -
Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain
por: Steigerwald, Ilona, et al.
Publicado: (2013) -
Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016) -
Cross-cultural adaptation, evaluation and validation of the Spouse Response Inventory: a study protocol
por: Kaiser, Ulrike, et al.
Publicado: (2014) -
Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)